Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-B49: pembrolizumab plus chemotherapy versus placebo plus chemotherapy in PD-L1-positive HR+/HER2- advanced breast cancer
MOH_2021-04-29_009931Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Pembrolizumab plus chemotherapy with Placebo plus chemotherapy (2 arms). Primary endpoints: Safety, Tolerability and 1 more. Started Mar 2021; status: active, not recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on MOH_2021-04-29_009931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-04-29_009931.